Board of Directors
Company Risk
If the Group is unable to offer products that can compete with competitors in the market in terms of both quality and price, it may result in the Group losing customers, which may have a material adverse impact on the revenue and operating results of the Group.
The Group recognizes this risk and therefore places importance on continuous research and development (RD) of products, including increasing product variety, developing new products, and enhancing the performance of existing products, leveraging knowledge, experience, and expertise in herbs accumulated over more than 25 years, together with the application of technology and innovation in product formulation development to create distinctive products that are differentiated from those of other manufacturers and that can rapidly respond to changing customer demands in line with market trends and consumer behavior, in another focus on blue ocean market. In addition, the Group places importance on quality control at every stage, from the selection of standardized raw material sources, through the production process, to product delivery, in order to maintain confidence and good relationships with existing customers, which is a critical factor in building competitive advantages that are difficult to replicate.
The Group may face the risk of ODM customers switching to other contract manufacturers and/or customers discontinuing existing products with the Group, which may have a material adverse impact on the revenue and operating results of the Group.
The Group recognizes this risk and therefore places importance on maintaining and developing good relationships with customers on a continuous basis, focusing on being a long-term business partner, while being able to rapidly offer new products aligned with market trends at appropriate prices to support customers’ competitiveness. This results in the Group receiving continuous trust and manufacturing engagements from customers. At the same time, the Group implements a Customer Diversification strategy to increase the diversity of its customer base, reduce dependence on any single customer, and strengthen long-term revenue stability. In addition, for products that customers commission SI to manufacture and that have been notified with the Food and Drug Administration (FDA) under SI’s name, such products must be manufactured according to the formula registered with SI only. Therefore, if such products become popular in the market, the likelihood of customers switching to other manufacturers is limited, as changing the manufacturing facility requires co-developing a new formula with the new manufacturer, which may result in product characteristics differing from the original formula.
The Group faces the risk that new products may not generate returns as expected, as the development and building of awareness for new products or brands requires high levels of investment in advertising, public relations, and sales promotion. However, in 2025, WELL was able to manage marketing expenses efficiently, resulting in a 49% decrease from the previous year, reflecting the ability to control costs alongside driving business growth.
The Company recognizes this risk. WELL has engage distributing partner which has expertise the planning and execution of marketing and sales g strategies to effectively reach target consumer groups. In addition, the Group is in the process of conducting clinical trials of “Colosure” dietary supplement in collaboration with the Faculty of Medicine, Chiang Mai University, in preparation for registration as a medical food or food for special medical purposes which will help expand distribution channels through the medical sector in the future.
If the Company is unable to retain its R&D personnel, or if knowledge or manufacturing formulas are leaked, it may result in the Company losing competitive advantages and impacting the continuity of the Group’s business operations.
The Company implements measures to retain R&D personnel with the organization in the long term through appropriate compensation and benefits, together with establishing measures to protect the Company’s critical knowledge, such as the execution of Non-Disclosure Agreements (NDAs) and the use of data storage systems with appropriate access restrictions. As a result, the turnover rate of R&D personnel decreased to 25% in 2024 and no resignations were recorded in 2025, reflecting the effectiveness of human resource management and the ability to control and reduce the risk of loss of the Company’s critical knowledge.
The Company may face the risk of volatility in the quantity and quality of herbal plants, which may result in the Group being unable to procure raw materials of adequate quality in sufficient quantities to meet demand, and being unable to deliver products to customers within the specified timeframe.
The Company procures raw materials through a network of farmer partners and community enterprises that have maintained business relationships for more than 10 years and are capable of delivering raw materials that meet the Company’s quality standards. The Company reserves herbal plant quantities in advance in line with the annual sales and production plans. In addition, for seasonal herbal raw materials that cannot be harvested year-round, the Group stores them in the form of concentrated crude extracts, which have a shelf life of up to 7 years, to ensure production continuity.
Consumers may file complaints or lawsuits seeking compensation from the Group, and there may be product recalls, production suspensions, or even revocation of relevant licenses, which may have a material adverse impact on the brand image, reputation, and financial performance of the Group.
The Company places the highest importance on product quality and safety by implementing effective quality control systems to strictly govern operations at every stage of the production process, through the QC/QA inspection system covering raw material procurement and inspection, storage, production, and product delivery. Operations comply with Good Manufacturing Practices and relevant international standards. The Group has obtained multiple internationally recognized quality certifications, including ISO 9001:2015, ISO 22716:2007, FSSC 22000, GMP, HACCP, GHPs, GMP PIC/S, and GHPP. The Group is also in the process of preparing for ISO/IEC 17025 accreditation to upgrade its laboratory capabilities to international standards, which will further strengthen competitive advantages and support continuous development in both quality and the organization’s technical capabilities.
The Group may face the risk of delays in or inability to renew licenses, as well as the risk of being unable to comply with new laws or criteria in a timely manner, which may incur additional costs for system or operational process improvements, and may result in restricted product distribution channels if new requirements are not met, potentially having a material adverse impact on the Group’s future business operations and financial position.
The Company closely monitors news and guidance from regulatory authorities, and has established a compliance governance structure with the Quality Management Representative (QMR) and Regulatory Affairs (RA) departments responsible for overseeing and ensuring that the Group complies fully with relevant laws and regulations, including timely license renewals and continuous monitoring of changes in laws and regulations, to enable effective and timely preparation and adaptation, thereby supporting uninterrupted business operations.
Changes in key management may impact the continuity of management and policy execution of the Group in the future, and may also affect the confidence of business partners and investors, particularly in the event of sudden changes.
Assoc. Prof. Dr. Panvipa Krisdaphong, as the founder of the Company, and the family, which holds approximately 74% of issued shares as major shareholders, ensures that key management will continue to play an important role in determining the overall policies and direction of the Group on a continuous basis. The Group has systematic management in place, with a clearly defined organizational structure, responsibilities, and approval authorities for each management level, in order to decentralize decision-making and reduce dependence on any single individual. In addition, the Group has established a Succession Plan, together with the development of Standardized Work systems, as well as policies for developing the capabilities of and creating incentives for executives and employees, to support business continuity and stable long-term growth.
Shareholder Risk
Other shareholders of the Company therefore face the risk of being unable to gather sufficient votes to scrutinize and counterbalance matters proposed by the major shareholder for consideration by the shareholders’ meeting.
The Company has appointed an Audit Committee to perform the function of auditing, considering, and screening to prevent transactions that may give rise to conflicts of interest in the future, and to ensure transparency in the Group’s operations. Furthermore, the Board of Directors structure comprises 4 independent directors (including the Chairman) out of a total of 8 directors, and 4 executive directors. Under the Public Company Act, in the event of a tie vote, the Chairman (who is an independent director), as the chairman of the meeting, has the right to cast an additional deciding vote. This Board structure ensures a balance of voting power in considering various matters and helps ensure that governance of management is appropriate and maximally effective.
Unlock full benchmarking
Claim this company to see every KPI your sector qualifies for, from 70+ across the market, benchmarked against sector peers.

